Discover open access scientific publications

Search, annotate, share and cite publications

Publications by L. Shun

P1.01-88 Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFRm-Positive Stage III NSCLC (LAURA)

Journal of Thoracic Oncology

English

Related publications

P1.01-80 ELIOS: A Multicenter, Open-Label, Molecular Profiling Study of Patients With EGFRm and NSCLC Treated With Osimertinib

Journal of Thoracic Oncology

English

MA05.01 E6508: Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Unresectable Stage III NS-NSCLC

Journal of Thoracic Oncology

English

OA01.07 Updated Results of a Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab in Patients With Unresectable Stage III NSCLC

Journal of Thoracic Oncology

English

P1.01-112 Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC

Journal of Thoracic Oncology

English

MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated With Durvalumab vs. Placebo After CRT

Journal of Thoracic Oncology

English

P3.17-12 Phase II Trial of Atezolizumab Before and After Chemoradiation for Unresectable Stage III NSCLC (AFT-16): Trial in Progress

Journal of Thoracic Oncology

English

P1.01-10 Stage III Non-Small Cell Lung Cancer Clinical Outcomes With Surgical Resection After Definitive Neoadjuvant Chemoradiotherapy

Journal of Thoracic Oncology

English

Prognostic Factors for Survival After Recurrence of Stage III Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Therapy

International Journal of Radiation Oncology Biology Physics

English

P2.01-58 Demographics, Clinical Characteristics and Treatment Sequencing in Stage III Unresectable NSCLC Patients: A Cancerlinq Cohort

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by L. Shun

P1.01-88 Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFRm-Positive Stage III NSCLC (LAURA)

Related publications

P1.01-80 ELIOS: A Multicenter, Open-Label, Molecular Profiling Study of Patients With EGFRm and NSCLC Treated With Osimertinib

MA05.01 E6508: Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Unresectable Stage III NS-NSCLC

OA01.07 Updated Results of a Phase II Trial of Concurrent Chemoradiation With Consolidation Pembrolizumab in Patients With Unresectable Stage III NSCLC

P1.01-112 Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC

MA05.02 PACIFIC Subgroup Analysis: Pneumonitis in Stage III, Unresectable NSCLC Patients Treated With Durvalumab vs. Placebo After CRT

P3.17-12 Phase II Trial of Atezolizumab Before and After Chemoradiation for Unresectable Stage III NSCLC (AFT-16): Trial in Progress

P1.01-10 Stage III Non-Small Cell Lung Cancer Clinical Outcomes With Surgical Resection After Definitive Neoadjuvant Chemoradiotherapy

Prognostic Factors for Survival After Recurrence of Stage III Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Therapy

P2.01-58 Demographics, Clinical Characteristics and Treatment Sequencing in Stage III Unresectable NSCLC Patients: A Cancerlinq Cohort